Pediatric patients with ulcerative colitis who fail conventional therapies may soon gain a new treatment option, as clinical trial results evaluate the safety and effectiveness of ustekinumab in younger populations, according to Dr. Jeffrey Hyams of the University of Connecticut and Connecticut Children’s Hospital. The UNIFI JR trial provides key data on the biologic therapy for children under 17, addressing a significant shortage of advanced medical interventions outside of anti-TNF agents.
UNIFI JR Trial Design and Patient Dosing Protocols
The UNIFI JR trial enrolled pediatric patients under the age of 17 who did not respond to conventional treatments like 5-ASA and steroids, according to Dr. Jeffrey Hyams. For patients weighing over 40 kg, the dose was weight-based. For those under 40 kg, dosing relied on body surface area to achieve consistent serum levels regardless of patient size.
Following the initial IV induction, maintenance therapy began at eight weeks. Patients received subcutaneous injections either every eight weeks or every 12 weeks. Researchers maintained the study blind by administering placebo subcutaneous injections, ensuring neither clinical staff nor patients knew which group was which through week 52. Only patients who responded to the drug at week eight moved forward in the trial.
Efficacy and Clinical Remission Rates in Children
Trial results for pediatric patients closely mirrored outcomes seen in adult clinical evaluations, according to Dr. Hyams. Clinical remission at week eight occurred in approximately 25% of patients, while roughly 70% achieved a clinical response.
Among the patients who responded at week eight, 49% of those assigned to the regimen every eight weeks maintained clinical remission at week 52. When calculated against the original cohort, that figure represents about 35% of the total study group. These consistent response and remission rates between children and adults suggest predictable pharmacological behavior across age groups.
Why Additional Advanced Therapies Matter for Pediatric Ulcerative Colitis
Advanced treatment options for children with ulcerative colitis remain limited primarily to anti-TNF agents, creating a therapeutic ceiling where no more than 50% to 60% of patients experience improvement, according to Dr. Hyams.
Data from the UNIFI JR trial indicate that safety profiles for ustekinumab are excellent, making it an attractive choice for patients who fail anti-TNF therapies. An open question remains regarding whether clinicians will adopt the drug as a primary advanced therapy.
Frequently Asked Questions
What is the primary goal of the UNIFI JR trial?
The trial gathers data on the safety and effectiveness of ustekinumab in pediatric patients with ulcerative colitis who do not respond to conventional therapies, according to Dr. Jeffrey Hyams.
How were pediatric doses determined in the study?
Dosing used a single IV induction approach where patients over 40 kg received weight-based dosing, while those under 40 kg received dosing based on body surface area.
What are the next steps for ustekinumab in pediatric care?
Researchers hope the data will lead to regulatory approval for ustekinumab as an additional treatment option for pediatric ulcerative colitis, according to Dr. Hyams.
Explore More: Read our latest coverage on advancements in pediatric gastroenterology or subscribe to our newsletter for clinical trial updates.
Keep reading